{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:06:18Z","timestamp":1783062378028,"version":"3.54.6"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gifu University Hospital Pharmacy Department Operation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The dexamethasone (DEX)-sparing strategy, which limits administration of DEX to day one, is reportedly non-inferior to conventional antiemetic regimens comprising multiple-day DEX. However, the usefulness of the DEX-sparing strategy in triplet antiemetic prophylaxis (neurokinin-1 receptor antagonist [NK1RA] + serotonin receptor antagonist [5HT3RA] + DEX) for carboplatin and moderate emetogenic chemotherapy (MEC) has not been clarified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>We systematically reviewed randomized controlled trials that examined the efficacy of antiemetics for preventing chemotherapy-induced nausea and vomiting associated with carboplatin and MEC. We conducted a network meta-analysis to compare the antiemesis efficacy of three-day DEX with NK1RA (3-DEX + NK1RA) and one-day DEX with NK1RA (1-DEX + NK1RA). The primary outcome was complete response during the delayed phase (CR-DP). The secondary outcome was no nausea during the delayed phase (NN-DP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventeen trials involving 4534 patients were included. The proportion who experienced CR-DP was 82.5% (95% credible interval [CI], 73.9-88.6) and 73.5% (95% CI, 62.8-80.9) among those who received 3-DEX + NK1RA and 1-DEX + NK1RA, respectively. There was no significant difference between the two regimens. However, 3-DEX + NK1RA tended to be superior to 1-DEX + NK1RA, with an absolute risk difference of 9.0% (95% CI, \u22122.3 to 21.1) in CR-DP and 24.7% (95% CI: \u221214.9 to 54.6) in NN-DP. 3-DEX + NK1RA also tended to be superior to 1-DEX + NK1RA in patients who received carboplatin-based chemotherapy, for whom the absolute risk difference was 12.3% (95% CI, \u22123.2 to 30.7).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Care is needed when administering the DEX-sparing strategy in combination with NK1RA to patients receiving carboplatin and non-carboplatin MEC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac060","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T20:10:30Z","timestamp":1647029430000},"page":"e524-e532","source":"Crossref","is-referenced-by-count":13,"title":["One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-0901","authenticated-orcid":false,"given":"Daichi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital , Gifu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital , Gifu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital , Gifu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Cancer Center, Gifu University Hospital , Gifu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital , Gifu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital , Gifu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"2","key":"2022060819293724400_CIT0001","first-page":"70","article-title":"Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy.","volume":"4","author":"Rowbottom","year":"2015","journal-title":"Ann Palliat Med"},{"issue":"5","key":"2022060819293724400_CIT0002","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","article-title":"A prospective &#x2028;observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01).","volume":"22","author":"Nakamura","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"2022060819293724400_CIT0003","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.","volume":"94","author":"Vardy","year":"2006","journal-title":"Br J Cancer"},{"issue":"5","key":"2022060819293724400_CIT0004","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","article-title":"Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"2022060819293724400_CIT0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/cas.12675","article-title":"Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.","volume":"106","author":"Komatsu","year":"2015","journal-title":"Cancer Sci"},{"issue":"8","key":"2022060819293724400_CIT0006","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.","volume":"19","author":"Celio","year":"2011","journal-title":"Support Care Cancer"},{"issue":"11","key":"2022060819293724400_CIT0007","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.","volume":"23","author":"Furukawa","year":"2015","journal-title":"Support Care Cancer"},{"issue":"3","key":"2022060819293724400_CIT0008","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00520-015-2905-4","article-title":"Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.","volume":"24","author":"Kosaka","year":"2016","journal-title":"Support Care Cancer"},{"issue":"12","key":"2022060819293724400_CIT0009","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","article-title":"One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis.","volume":"24","author":"Okada","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"2022060819293724400_CIT0010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","article-title":"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence.","volume":"19","author":"Celio","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"2022060819293724400_CIT0011","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy.","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022060819293724400_CIT0012","author":"NCCN"},{"issue":"1","key":"2022060819293724400_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","article-title":"Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.","volume":"26","author":"Aogi","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"24","key":"2022060819293724400_CIT0014","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update.","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022060819293724400_CIT0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy.","volume":"25","author":"Roila","year":"2017","journal-title":"Support Care Cancer"},{"issue":"2","key":"2022060819293724400_CIT0016","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","article-title":"A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan.","volume":"25","author":"Iihara","year":"2020","journal-title":"Oncologist"},{"issue":"9","key":"2022060819293724400_CIT0017","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1007\/s00520-021-06061-8","article-title":"Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score\u2013matched analysis.","volume":"29","author":"Hayashi","year":"2021","journal-title":"Support Care Cancer"},{"issue":"2","key":"2022060819293724400_CIT0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1740774513498322","article-title":"Network meta-analysis of randomized clinical trials: reporting the proper summaries.","volume":"11","author":"Zhang","year":"2014","journal-title":"Clin Trials"},{"key":"2022060819293724400_CIT0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18637\/jss.v080.i05","article-title":"Performing arm-based network meta-analysis in R with the pcnetmeta package.","volume":"80","author":"Lin","year":"2017","journal-title":"J Stat Softw"},{"key":"2022060819293724400_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/497597","article-title":"Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara.","volume":"2015","author":"Badar","year":"2015","journal-title":"Biomed Res Int"},{"issue":"1","key":"2022060819293724400_CIT0021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cam4.2628","article-title":"Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: a randomized, controlled study from the \u201cRete Ematologica Pugliese\u201d.","volume":"9","author":"Di Renzo","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"2022060819293724400_CIT0022","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00520-011-1235-4","article-title":"Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.","volume":"20","author":"Hesketh","year":"2012","journal-title":"Support Care Cancer"},{"issue":"6","key":"2022060819293724400_CIT0023","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s10147-015-0823-6","article-title":"Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.","volume":"20","author":"Kitayama","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"30","key":"2022060819293724400_CIT0024","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","article-title":"Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.","volume":"32","author":"Schmitt","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022060819293724400_CIT0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12325-018-0862-2","article-title":"Efficacy, tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy: a randomized controlled trial.","volume":"36","author":"Xiong","year":"2019","journal-title":"Adv Ther"},{"issue":"8","key":"2022060819293724400_CIT0026","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00520-003-0488-y","article-title":"Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan.","volume":"11","author":"Inoue","year":"2003","journal-title":"Support Care Cancer"},{"issue":"3","key":"2022060819293724400_CIT0027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/mco.2015.724","article-title":"A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.","volume":"4","author":"Aridome","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"8","key":"2022060819293724400_CIT0028","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.","volume":"19","author":"Celio","year":"2011","journal-title":"Support Care Cancer"},{"issue":"11","key":"2022060819293724400_CIT0029","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.","volume":"23","author":"Furukawa","year":"2015","journal-title":"Support Care Cancer"},{"issue":"3","key":"2022060819293724400_CIT0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","article-title":"Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.","volume":"84","author":"Ito","year":"2014","journal-title":"Lung Cancer"},{"key":"2022060819293724400_CIT0031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.","volume":"9","author":"Kaushal","year":"2015","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"2022060819293724400_CIT0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00520-016-3463-0","article-title":"Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.","volume":"25","author":"Kim","year":"2017","journal-title":"Support Care Cancer"},{"issue":"3","key":"2022060819293724400_CIT0033","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","article-title":"Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.","volume":"90","author":"Kusagaya","year":"2015","journal-title":"Lung Cancer"},{"issue":"8","key":"2022060819293724400_CIT0034","first-page":"4527","article-title":"Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin.","volume":"35","author":"Maehara","year":"2015","journal-title":"Anticancer Res"},{"issue":"10","key":"2022060819293724400_CIT0035","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jog.12748","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: a randomized, multicenter, phase-II trial.","volume":"41","author":"Matsuura","year":"2015","journal-title":"J Obstet Gynaecol Res"},{"issue":"10","key":"2022060819293724400_CIT0036","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.","volume":"51","author":"Nishimura","year":"2015","journal-title":"Eur J Cancer"},{"issue":"4","key":"2022060819293724400_CIT0037","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"issue":"9","key":"2022060819293724400_CIT0038","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","article-title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled.","volume":"16","author":"Schwartzberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2022060819293724400_CIT0039","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/jog.13378","article-title":"A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.","volume":"43","author":"Sugimori","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"2022060819293724400_CIT0040","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"2022060819293724400_CIT0041","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annonc\/mdv482","article-title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.","volume":"27","author":"Weinstein","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"2022060819293724400_CIT0042","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","article-title":"Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"15","key":"2022060819293724400_CIT0043","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/cncr.30054","article-title":"Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.","volume":"122","author":"Hesketh","year":"2016","journal-title":"Cancer"},{"key":"2022060819293724400_CIT0044","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"2022060819293724400_CIT0045","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"2022060819293724400_CIT0046","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","article-title":"Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.","volume":"18","author":"Tsuji","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2022060819293724400_CIT0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10549-015-3669-8","article-title":"Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.","volume":"155","author":"Ng","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2022060819293724400_CIT0048","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?","volume":"20","author":"Ng","year":"2015","journal-title":"Oncologist"},{"issue":"11","key":"2022060819293724400_CIT0049","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00520-015-2801-y","article-title":"Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients\u2019 experience.","volume":"23","author":"Hernandez Torres","year":"2015","journal-title":"Support Care Cancer"},{"issue":"32","key":"2022060819293724400_CIT0050","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","article-title":"Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study.","volume":"30","author":"Albany","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022060819293724400_CIT0051","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.","volume":"28","author":"Tan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2022060819293724400_CIT0052","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.","volume":"24","author":"Chow","year":"2016","journal-title":"Support Care Cancer"},{"issue":"5","key":"2022060819293724400_CIT0053","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.","volume":"9","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"issue":"10","key":"2022060819293724400_CIT0054","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study.","volume":"26","author":"Celio","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"2022060819293724400_CIT0055","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/cas.14757","article-title":"5HT3RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer.","volume":"112","author":"Hayashi","year":"2021","journal-title":"Cancer Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/6\/e524\/43984403\/oyac060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/6\/e524\/43984403\/oyac060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T19:30:22Z","timestamp":1654716622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/6\/e524\/6569130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,15]]},"published-print":{"date-parts":[[2022,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac060","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,15]]}}}